Lilly, Boehringer tweak diabetes alliance terms; Judges scrutinize Ackman's Allergan share before vote;

@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Production issues for $GSK, Sanofi delay flu vaccines in the U.S. Article | Follow @FiercePharma

@EricPFierce: Ranbaxy's Ohm Laboratories plant comes to the rescue in last quarter, turning bottom line from red to black. FiercePharmaManufacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce

> Eli Lilly ($LLY) and Boehringer Ingelheim have revised the terms of their diabetes drugs alliance in some countries. Report

> A judge is examining Bill Ackman's accumulation of $5.3 billion of Allergan ($AGN) stock to decide whether he can vote his 9.7% stake at Allergan's Dec.18 special shareholder meeting. More

> Indian drugmaker Dr. Reddy's missed the Street's latest quarterly estimates on muted U.S. growth and a sharp decline in Russia. Report

> A fund to pay for cancer drugs that are not available on the U.K.'s National Health Service "papers over" deeper drug pricing issues, a charity says. More

Medical Device News

@FierceMedDev: ICYMI yesterday: Welch Allyn partners with startup Gentag to create wearable devices. Article | Follow @FierceMedDev

@VarunSaxena2: UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring. More | Follow @VarunSaxena2

@EmilyWFierce: Au revoir, Viehbacher. Reuters article | Follow @EmilyWFierce

> J&J Innovation's Ken Drazan on the future of med tech. Editor's Corner

> Medtronic announces first U.S. implant of investigational aortic heart valve. Article

Biotech News

@FierceBiotech: Armed with $48M bankroll, Aileron sets sights on p53 tumor target. Article | Follow @FierceBiotech

@JohnCFierce: $JNJ in China, deals getting struck on drug rights. Lots coming in Asia for biopharma. It's the new, new thing | Follow @JohnCFierce

@DamianFierce: "Categorical" second only to "fundamental" in corporate nonsensespeak--$AEGR. More from TheStreet | Follow @DamianFierce

@EmilyMFierce: Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. FierceBiotech Research story | Follow @EmilyMFierce

> Cara's pain drug clears an abuse hurdle as it trots toward Phase III. News

> Xencor moves on without Amgen, ditching its hopes in arthritis. More

> Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China. Article

Drug Delivery News

> Eye care company pSivida receives royalty payment, will spend it on pipeline. More

> BDSI aiming to develop injectable buprenorphine. Item

> Harvard team uses stem cells to deliver toxic doses to cancer cells. Report

> Microscale fibers may have many drug-delivery uses. Story

> Pfizer to withdraw from partnership to develop tamper-proof oxycodone formulation. Article

Diagnostics News

> InSilixa ropes in $13M from PointGuard Ventures and Morningside for molecular Dx tests. Story

> Johns Hopkins scientists develop real-time diagnostic system for drug-resistant bacteria. More

> FDA grants bioMérieux emergency authorization for one-hour Ebola Dx. Item

> 'See-through' sensors for the brain are transparent to imaging diagnostics. Story

> French scientists roll out rapid diagnostic test for Ebola. Article

Pharma Marketing News

> Love to hate Mr. Mucus? The Mucinex snot monster is back with a McCann makeover. Report

> For Novartis' respiratory ambitions, it's a tale of 'two worlds.' Story

> Sanofi board ousts CEO, aiming for a more 'cooperative' chief. Item

> Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo? More

> Orphan drug pricing for non-orphan meds? Express Scripts is looking at you, Gilead. Article

And Finally... In an insider trading probe, the SEC is innvestigating whether CMS employees leaked news on Dendreon's ($DNDN) Provenge. Report (sub. req.)

Suggested Articles

Creating a relevant online health user experience has its payoffs — for both the user and the brand. Here’s why.

Sanofi's new strategy delivered for the drugmaker in the third quarter as Dupixent posted blockbuster sales and flu vaccines set a revenue record.

Catalent has acquired Bone Therapeutics' cell and gene therapy site in Gosselies, Belgium, to add to its growing "center of excellence" there.